Related Experiment Video
Updated: May 30, 2026
The MUB40 Peptide for Use in Detecting Neutrophil-Mediated Inflammation Events
Published on: January 7, 2019
Discovery and development of a synthetic peptide derived from lactoferrin for clinical use
Carlo P J M Brouwer1, Mahfuzur Rahman, Mick M Welling
1Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Room C4-R-77, Leiden, The Netherlands.
Abstract:
There is an urgent need to develop new antimicrobial drugs especially for combating the rise of infections caused by multi-resistant pathogens such as MRSA and VRSA. The problem of antibiotic resistant micro-organisms is expected to increase disproportionally and controlling of infections is becoming difficult because of the rapid spread of those micro-organisms. Primary therapy with classical antibiotics is becoming more ineffective. Combinational therapy of antibiotics with antimicrobial peptides (AMP's) has been suggested as an alternative approach to improve treatment outcome. Their unique mechanism of action and safety profile makes AMP's appealing candidates for simultaneous or sequential use in different cases of infections. In this review, for antimicrobial treatment the application of synthetic antimicrobial peptide hLF(1-11), derived from the first 11 amino acids of human lactoferrin is evaluated in both pre-clinical and clinical settings. Present information indicates that this derivate from lactoferrin is well tolerated in pre-clinical tests and clinical trials and thus hLF(1-11) is an interesting candidate for further exploration in various clinical indications of obscure infections, including meningitis. Another approach of using AMP's is their use in prevention of infections e.g. as coating for dental or bone implants or in biosensing applications or useful as infection specific radiopharmaceutical.
Insights
New antimicrobial peptides (AMPs) show promise against drug-resistant bacteria. Synthetic human lactoferrin peptide hLF(1-11) is well-tolerated in trials, offering a potential new strategy for treating difficult infections.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- Rising antibiotic resistance in pathogens like MRSA and VRSA necessitates novel antimicrobial strategies.
- Conventional antibiotic therapies are increasingly ineffective against multi-drug resistant infections.
- Combinational therapy with antimicrobial peptides (AMPs) presents a promising alternative to enhance treatment efficacy.
Purpose of the Study:
- To review the application of synthetic antimicrobial peptide hLF(1-11) in antimicrobial treatment.
- To evaluate the efficacy and safety of hLF(1-11) in pre-clinical and clinical settings.
- To explore the potential of hLF(1-11) for various clinical indications and other applications.
Main Methods:
- Literature review of pre-clinical and clinical studies on hLF(1-11).
- Analysis of safety and tolerability data from trials.
- Exploration of diverse applications of AMPs, including hLF(1-11).
Main Results:
- The synthetic antimicrobial peptide hLF(1-11), derived from human lactoferrin, is well-tolerated in pre-clinical tests and clinical trials.
- hLF(1-11) demonstrates potential as a candidate for treating obscure infections, including meningitis.
- AMPs offer versatile applications, such as implant coatings, biosensing, and radiopharmaceuticals.
Conclusions:
- hLF(1-11) is a promising candidate for further exploration in antimicrobial treatment due to its safety profile.
- Antimicrobial peptides represent a valuable class of compounds for combating antibiotic resistance.
- The diverse applications of AMPs highlight their broad potential in medicine and biotechnology.
